Journal of Thrombosis and Thrombolysis

, Volume 35, Issue 3, pp 387–390

Monitoring target specific anticoagulants


DOI: 10.1007/s11239-013-0880-5

Cite this article as:
Konkle, B.A. J Thromb Thrombolysis (2013) 35: 387. doi:10.1007/s11239-013-0880-5


New, target specific, oral anticoagulants have been shown to be safe and effective in prevention and treatment of thromboembolism without laboratory monitoring. However, clinical use of the drugs dabigatran, rivaroxaban, and apixaban requires laboratory measurement of their anticoagulant effect in specific clinical situations. This paper reviews the data available on use of screening and specialized testing to measure the anticoagulant effect and drug levels in patients prescribed these medications. Their effect on other coagulation assays is also reviewed.


Dabigatran Rivaroxaban Apixaban Coagulation testing Monitoring 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Hemostasis Reference LaboratoryClinical and Translational Research, Puget Sound Blood Center, University of Washington School of MedicineSeattleUSA

Personalised recommendations